1. Home
  2. SNX vs INM Comparison

SNX vs INM Comparison

Compare SNX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TD SYNNEX Corporation

SNX

TD SYNNEX Corporation

HOLD

Current Price

$152.68

Market Cap

12.6B

Sector

Technology

ML Signal

HOLD

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

HOLD

Current Price

$1.13

Market Cap

3.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNX
INM
Founded
1980
1981
Country
United States
Canada
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6B
3.7M
IPO Year
2003
N/A

Fundamental Metrics

Financial Performance
Metric
SNX
INM
Price
$152.68
$1.13
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$168.60
N/A
AVG Volume (30 Days)
779.5K
159.3K
Earning Date
01-08-2026
02-11-2026
Dividend Yield
1.15%
N/A
EPS Growth
18.98
N/A
EPS
9.21
N/A
Revenue
$60,973,509,000.00
$4,798,116.00
Revenue This Year
$7.25
N/A
Revenue Next Year
$4.35
N/A
P/E Ratio
$16.67
N/A
Revenue Growth
6.94
N/A
52 Week Low
$92.23
$1.03
52 Week High
$167.76
$8.27

Technical Indicators

Market Signals
Indicator
SNX
INM
Relative Strength Index (RSI) 49.84 39.32
Support Level $149.96 $1.03
Resistance Level $155.06 $1.35
Average True Range (ATR) 3.05 0.10
MACD -0.16 -0.00
Stochastic Oscillator 49.30 22.22

Price Performance

Historical Comparison
SNX
INM

About SNX TD SYNNEX Corporation

TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.

Share on Social Networks: